TANG KEVIN purchased $27K of BOLD (indirect holdings)

TANG KEVIN purchased 11,162 indirectly-held shares of Boundless Bio, Inc. (BOLD) at $2.40 across 3 trades over 2026-11-03 to 2026-11-05. Filed jointly with TANG CAPITAL MANAGEMENT LLC (10% owner).

Original reporting
SEC EDGAR · TANG KEVIN, TANG CAPITAL MANAGEMENT LLC
Published Nov 5, 2026, 11:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 11:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BOLD
Neutral
high confidence
Mentioned
$BOLD
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLDNeutralLow
01

Why it matters

The filing is a primary disclosure but the transaction size is trivial, offering limited trading insight.

02

Market read

Minimal impact; the insider purchase is too small to affect price materially.

03

What to watch

Kevin Tang already holds a large stake; additional shares may have little incremental meaning.

Relevance 4/10Novelty 3/10Timing: today

Background

Boundless Bio, Inc. (BOLD) filed a Form 4 indicating a $27K insider purchase by a 10% owner.

Company-level read

Ticker impact

$BOLDNeutralHigh confidence
Context

Form 4 shows insider Kevin Tang bought 11,162 shares for $26,788.80, increasing his stake to over 3 million shares.

Expected impact

minor upward pressure as market prices in insider buying

Evidence & confidence

The transaction is a primary filing, but the dollar amount is under $30k, unlikely to move the stock materially.

Market effects

None; insider activity does not affect the broader biotech sector.

None; transaction is company‑specific.

None

Counterpoint

The purchase could be a routine portfolio rebalancing rather than a bullish signal.

Key entities

  • Boundless Bio, Inc.

    Biotech firm listed on US exchanges under ticker BOLD.

  • Kevin Tang

    10% owner of Boundless Bio who made the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BOLDMed

Boundless Bio 3Q 2026: EPS ($0.23) — 10-Q Summary

Boundless Bio reported a 61.4% narrower net loss of $5.36M in Q3 2026, with EPS at ($0.23). The reduction was driven by lower clinical-trial spending, reduced facilities, and personnel costs. The company also announced a 75% workforce reduction and expects a merger with Serapha Bio to close in Q4 2026, with a pre-closing dividend of $44M-$48M.